TrialBMC cancer2024

Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.

Bo Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.